October 7, 2024

UPDATE: FDA Places Kezar Life Sciences’ Phase 2b Study of Zetomipzomib for Lupus Nephritis Treatment on Clinical Hold – Lupus Foundation of America

October 2, 2024

Recent advances in the diagnosis and management of neuropsychiatric lupus – Nature.com

September 30, 2024

Kezar halts dosing and enrollment in key lupus study after 4 patient deaths – Fierce Biotech

September 26, 2024

UPDATE: Positive Phase III Clinical Trial Results Announced for Gazyva for the Treatment of Lupus Nephritis – Lupus Foundation of America

September 24, 2024

Biogen, UCB get the lupus data they’ve waited two decades for – BioPharma Dive